CING Cingulate Inc.

Nasdaq cingulate.com


$ 3.57 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 15:57:44 EDT
QQQ $ 611.38 $ 0.00 (0 %)
DIA $ 466.73 $ 1.78 (0.38 %)
SPY $ 671.88 $ 3.53 (0.53 %)
TLT $ 91.42 $ 0.00 (0 %)
GLD $ 378.74 $ -2.69 (-0.71 %)
$ 3.65
$ 3.64
$ 3.60 x 5
$ 3.80 x 10
$ 3.56 - $ 3.64
$ 3.02 - $ 6.01
238,914
na
19.76M
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-19-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-10-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cingulates-data-from-lead-adhd-candidate-ctx-1301-selected-for-podium-presentation-at-aacap-annual-meeting-in-chicago

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical...

 roth-capital-maintains-buy-on-cingulate-raises-price-target-to-17

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10...

 cingulate-announces-that-us-fda-accepts-for-review-its-new-drug-application-for-ctx-1301-its-lead-adhd-treatment-candidate-for-children-and-adults

Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical ...

 cingulate-enters-commercial-supply-agreement-with-bend-bio-sciences-for-manufacturing-of-ctx-1301-its-lead-drug-candidate-for-treating-adhd

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delive...

 ascendiant-capital-maintains-buy-on-cingulate-raises-price-target-to-62

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.

 cingulate-q2-eps-109-misses-084-estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) b...

 cingulate-appoints-jennifer-callahan-as-interim-ceo-names-jay-roberts-executive-chairman

Jennifer Callahan, Chief Financial Officer, appointed Interim CEOBoard member, Jay Roberts appointed Executive ChairmanKANSAS C...

 cing-cingulate-enters-25m-purchase-agreement-with-lincoln-park

-SEC Filing

 ascendiant-capital-maintains-buy-on-cingulate-raises-price-target-to-61

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $60 to $61.

 roth-capital-maintains-buy-on-cingulate-lowers-price-target-to-11

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $12...

 cingulate-receives-formal-pre-nda-meeting-minutes-from-fda-for-ctx-1301-in-adhd

Details of the FDA's minutes include the following, all of which will be a matter of review during the approval process:The...

 cingulate-q1-eps-104-misses-092-estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.92) b...

 ascendiant-capital-maintains-buy-on-cingulate-lowers-price-target-to-60

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $75 to $60.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION